

# Multiple Myeloma Market 2023 Trends: Predicted to Grow at a CAGR of 10.5% by 2031

*The multiple myeloma market size is projected to reach \$53,521.76 million by 2031, registering a CAGR of 10.5% from 2022 to 2031.*

PORTLAND, OREGON, UNITED STATES, July 11, 2023 /EINPresswire.com/ -- The [multiple myeloma market](#) size was valued at \$19,666.74 million in 2021, and is projected to reach \$53,521.76 million by 2031, registering a CAGR of 10.5% from 2022 to 2031.



Multiple myeloma is a form of cancer that impacts plasma cells, a specific type of white blood cell crucial for defending against infections. This condition leads to the creation of abnormal proteins known as paraproteins, which can accumulate in the body and harm organs and tissues. Common symptoms of multiple myeloma encompass bone pain, anemia, recurring infections, and kidney complications. Available treatment options involve chemotherapy, radiation therapy, targeted therapy, and stem cell transplantation.

For more information, please contact Allied Market Research at [sales@alliedmarketresearch.com](mailto:sales@alliedmarketresearch.com) or visit our website at <https://www.alliedmarketresearch.com/request-sample/3725>

The global multiple myeloma market is driven by several key factors, including the increasing focus on research and development activities in the field of cancer treatment and the rapid introduction of new medications with regulatory approvals. The market has been positively influenced by the advent of monoclonal antibodies (mAbs) such as Empliciti and Darzalex, which have made significant contributions to its growth. A noteworthy example is the FDA approval in March 2020 of Sarclisa (isatuximab-irfc) by Sanofi, a prominent multinational pharmaceutical and healthcare company. Sarclisa, in combination with pomalidomide and dexamethasone (pom-dex), was approved for the treatment of adults with relapsed refractory multiple myeloma (RRMM). This development has further propelled the expansion of the global multiple myeloma market.

□□□ □□□□□□ □□□□□□ □□□□□□ □□ □□□□ □□ □□□□ □□□□□□ □□□□□□:

Which are the driving factors responsible for the growth of market?

Which are the roadblock factors of this market?

What are the new opportunities, by which market will grow in coming years?

What are the trends of this market?

Which are main factors responsible for new product launch?

How big is the global & regional market in terms of revenue, sales and production?

How far will the market grow in forecast period in terms of revenue, sales and production?

Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?

How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?

Which region has more opportunities?

□□□□□□ □□□□□□ □□□□□□ (411+ □□□□ □□ □□□ □□□□□□, □□□□□□, □□□□□□, □□□ □□□□□□:

<https://www.alliedmarketresearch.com/multiple-myeloma-market/purchase-options>

□□□ □□□□□□□ □□ □□□□□□□□□□□□

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the multiple myeloma market analysis from 2021 to 2031 to identify the prevailing multiple myeloma market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the multiple myeloma market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global multiple myeloma market trends, key players, market segments, application areas, and market growth strategies.

□□□□ □□□ □□□□□? □□□ □□□ □□□□□□ @: <https://www.alliedmarketresearch.com/purchase-enquiry/3725>

□□□ □□□□□□□□ □□□□□□ □□□□□□□□□□

Sanofi

Takeda Pharmaceutical Company Ltd

AbbVie Inc

Pfizer Inc.

Novartis AG  
Baxter International Inc.  
Bristol-Myers Squibb Company  
Teva Pharmaceutical Industries  
Johnson & Johnson  
Amgen Inc.

□□□ □□□□□□□□ □□ □□□ □□□□□

- By drug type, the protease inhibitor segment dominated the market in 2021.
- On the basis of disease type, the active multiple myeloma segment led the market in 2021.
- Depending on end user, hospitals was the prominent segment in 2021.
- Region wise, North America exhibited the highest growth in 2021, and is expected to grow during the forecast period.

□□□ □□□□□□□□ □□□□□□ □□ □□□□ □□□□□□ □□□□□□-

□□□□□□ □□□□□□ □□□□□□ <https://www.alliedmarketresearch.com/gastric-cancer-market-A74458>

□□□□□ □□□□□□□□ □□□□□ □□□□□□ <https://www.alliedmarketresearch.com/blood-pressure-cuffs-market-A11934>

□□□□□ □□□□ □□□□□□□□□□ □□□□□□ <https://www.alliedmarketresearch.com/joint-pain-injections-market-A31459>

David Correa  
Allied Analytics LLP  
+1 800-792-5285  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/644034524>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.